Concomitant secretion of prourokinase and of a plasminogen activator- specific inhibitor by cultured human monocytes-macrophages by unknown
CONCOMITANT  SECRETION  OF  PROUROKINASE  AND  OF 
A  PLASMINOGEN  ACTIVATOR-SPECIFIC  INHIBITOR  BY 
CULTURED  HUMAN  MONOCYTES-MACROPHAGES 
By JEAN-DOMINIQUE VASSALLI, JEAN-MICHEL DAYER,* 
ANNELISE WOHLWEND, AND DOMINIQUE BELIN  ~ 
From the Institute of Histology and Embryology, *the Division of Immunology and Allergy, 
Department of  Medicine, Sand the Department of Pathology, University of Geneva Medical School, 
1211 Geneva 4, Switzerland 
Piasminogen  activators  (PA) l  are  thought  to  play a  role  in  the  proteolytic 
events associated with cell migration  and tissue destruction and remodeling (1), 
in particular  in the context of inflammation  (2).  Indeed,  monocytes and macro- 
phages from both human and murine origin produce PA (3, 4), and the secretion 
of these enzymes has been linked with the participation  of mononu¢lear phago- 
cytes in inflammatory reactions:  peritoneal  macrophages collected from inflam- 
matory exudates synthesize and secrete such enzymes (reference  3,  D.  Belin et 
al.,  manuscript  in  preparation);  furthermore,  PA  production  is  enhanced  by 
inflammatory agents (5,  6) and suppressed by antiinflammatory  glucocorticoids 
(2).  However, little  is known  at  the  molecular level about  the  mechanisms  by 
which PA activity is regulated. 
Recently progress has been made in the characterization of PA. Two different 
enzymes, urokinase (Uk) and tissue activator (TA), have been identified.  Their 
primary  structures  have been  elucidated at  the protein  or mRNA level  (7-9), 
and it is now clear that they are the products of different genes. Aspects of their 
biosynthesis have been investigated.  Uk has been shown to be secreted by certain 
human  and  murine  cells as a  one-chain  inactive zymogen, with a Mr of 55,000 
for  the  human  protein  (10-12).  Active  Mr  55,000  human  Uk  is  generated 
through a single intramolecular proteolytic cleavage, and consists of two disulfide- 
linked polypeptide chains. Mr 33,000 human  Uk is a proteolytic product of the 
Mr 55,000 enzyme with similar specific catalytic activity. The cellular production 
of PA inhibitors has also been described: in particular the secretion of protease- 
nexin (13) by human fibroblasts has been suggested to play a role in the regulation 
of  extracellular  PA  activity  (14);  mouse  peritoneal  macrophages  have  been 
reported to be a source of such inhibitors (15,  16). 
In view of these developments, it was of interest to determine the type of PA 
produced in cultures of human monocytes-macrophages, as well as to investigate 
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the possible secretion of PA inhibitors by these cells.  In this communication we 
show  that  both  freshly  isolated  human  peripheral  blood  monocytes  and  ceils 
from the monocytic line U  937 (17) secrete Uk, mostly in the form of the inactive 
zymogen. Concomitantly, these cells also release a PA-specific protease inhibitor. 
Materials and  Methods 
Materials.  Rabbit antibodies to human urinary Uk (18) and to human HeLa cells TA, 
as well as conditioned medium from phorbol myristate acetate (PMA)-treated HeLa cells, 
were the kind gift of Dr. W.-D. Schleuning. Controls for the specificity of these antibodies 
with respect to the two different types of PA are included in the experiment of Fig.  1. 
IgG were prepared by Protein A-Sepharose chromatography (19). Mr 55,000 Uk (1.5 x 
105  U/mg) was from the  Green  Cross Corporation,  Osaka, Japan; MT  33,000  Uk was 
generously provided by Serono, Denens, Switzerland. Thrombin from human plasma (T 
6759) was from Sigma Chemical Co. (St.  Louis, MO), and bovine serum albumin (BSA, 
11920) from Serva Feinbiochemica (Heidelberg, Federal Republic of Germany). Percoll 
was obtained from Pharmacia Fine Chemicals (Piscataway, N  J). Plasminogen was purified 
from human  plasma (20);  plasmin  was prepared  by  Uk  activation in  the presence  of 
glycerol as described (21).  RPMI  1640,  fetal bovine serum (FBS),  and Ca+÷-Mg  ++ free 
Hank's balanced  salt  solution  (HBSS)  were  from Grand  Island  Biological  Co.  (Grand 
Island, NY), diisopropyl-fluoro-phosphate (DFP) and Triton X-100  from Merck & Co., 
Inc. (Rahway, N  J), sodium dodecyl sulfate (SDS) from Bio-Rad Laboratories (Richmond, 
CA),  Iodogen  from  Pierce  Chemical  Co.  (Rockford,  IL),  acrylamide,  bisacrylamide, 
N,N,N',N',-tetramethylethylenediamine  and ammonium persulfate from Eastman Kodak 
Co. (Rochester, NY), and Na [~5I] from Amersham Corp. (Arlington Heights, IL). Tissue 
culture plasticware was obtained from Falcon Labware (Oxnard, CA). 
Cell  Culture.  U  937  cells were obtained from Dr.  R.  Snyderman (Duke  University 
Medical Center,  Durham, NC), grown in RPMI  1640  supplemented with 5%  FBS,  and 
cultures were split 1 to 3, every 4 d. To prepare conditioned media the cells were collected 
by centrifugation, washed, and incubated at 2 x  106/ml as described below. Monocytes 
were prepared from freshly drawn citrated human blood by Ficoll-Hypaque sedimentation 
(22) after dilution with 2 volumes of HBSS; the blood mononuclear cells were layered on 
a preformed Percoll gradient (12,900 g for 4 min 30 s at 4°C in a Beckman superspeed 
J2-21  centrifuge using the JA 20.1  rotor). The gradient was centrifuged for 4 min 30 s 
at 8,240 g in the same rotor. The monocytes (upper cell layer) were washed and plated at 
2 x  106/ml in RPMI 1640 supplemented with 10% heat-inactivated (56°C, 45 min) FBS. 
After 2 h at 37°C, adherent cells were washed and incubated as described below. Purified 
cells were analyzed by staining for nonspecific esterase (23) and peroxidase (24) and found 
to be >98% monocytes. Human foreskin fibroblasts were grown in RPMI 1640 plus 5% 
FBS,  and  used  at passage  10;  confluent  cultures  in  35-mm tissue  culture  dishes  were 
washed and  incubated with  1 ml serum-free medium as described  below.  To prepare 
conditioned  media,  cells were washed 3  times in  RPMI  1640  with  1 mg/ml BSA and 
cultured in RPMI  1640 plus  1 mg/ml BSA for 24-48 h  at 37°C in a 95% air-5% CO2 
atmosphere. At the end of the culture period the media were collected, spun twice for 10 
rain at 500 g to remove cells and debris, and stored at -20°C. Cell viability was assessed 
by trypan blue exclusion; 98% of the ceils excluded the dye after 24 h, and 92-95% after 
48 h of culture in RPMI 1640 plus 1 mg/ml BSA. 
Immunoprecipitation.  Samples (20 #1) were mixed with 2 ul of anti-human Uk (0.2 rag/ 
ml), anti-human TA (1  mg/ml), or irrelevant (1  mg/ml) IgG, and incubated for 2 h at 
4°C. Fixed S. aureus (I 5 #1), prepared according to Kessler (25), were added; after 30 rain 
at 20 °C, the samples were centrifuged (5 rain, Beckman Microfuge; Beckman Instruments, 
Inc., Palo Alto, CA). Supernatants were mixed with an equal volume of double strength 
electrophoresis sample buffer (0.1  M Tris-CI, pH 6.8, 2% SDS,  20% glycerol). Pellets of 
the  Uk,  monocyte, and  U  937  medium immunoprecipitations were washed twice with 
PBS containing  1 mg/ml BSA, and eluted in 50 #1 electrophoresis sample buffer. Pellets 
of the TA immunoprecipitations were washed 3 times with NET-TS (NaCI 0.5 M, EDTA VASSALLI  ET  AL.  1655 
0.001  M,  Tris-Cl 0.05  M pH  8.1, Triton X-100  1%, SDS 0.2%)  and once with NT-S 
(NaCI 0.5  M, Tris-Cl 0.05  M pH  8.1, SDS 0.1%) before elution in sample buffer; this 
modification was introduced to overcome nonspecific adsorption of TA to S. aureus. 
SDS Polyacrylamide Gel Electrophoresis.  Samples (15/~l) were electrophoresed at 20 mA 
constant current in 10% polyacrylamide slab gels (0.8  mm thick and 5.5 cm long), using 
the buffer system of Laemmli (26); all gels were run under nonreducing conditions. 
Zymographic Assay for PA.  The method described by Granelti-Piperno and Reich (21) 
was used; the electrophoretic gels were shaken for 20 min in 2.5% Triton X-100 in H20 
followed by 20  min in PBS before being layered on the substrate gels.  Substrate gels 
consisted of a mixture of 0.8% agar, 1.3% Carnation instant non-fat dry milk, 40 #g/ml 
plasminogen in PBS; the mixture was prepared at 45°C, cast onto a flat glass or plastic 
surface, and allowed to solidify at 20°C before use. Zymograms were allowed to develop 
at 37 °C for 5-30 h. Photographs were taken using dark-ground illumination. 
[az51]-Fibrin Plate Assay.  This was performed exactly as described (27). 
[125I]-Labeling of Uk  and  Thrombin.  These proteins were  labeled using Iodogen as 
described (13), except that spun Sephadex G-50 columns (28) were used to separate the 
proteins from unreacted [~2~I]. The specific activities of the [tzsI]2proteins were as follows: 
Mr 55,000 Uk, 1-2 ×  107 cpm/~g; Mr 33,000 Uk, 0.8-1.7 ×  107 cpm//~g; thrombin, 3 × 
106  cpm//~g.  Two  radioactive polypeptides were present  in  the preparation  of [l~sI]- 
thrombin (Fig. 8, track I): an unidentified contaminant of Mr 20,000, and thrombin itself, 
with an Mr of 34,000. 
Autoradiography.  Fixed and stained gels (0.2%  Coomassie Brilliant Blue R250 in 30% 
methanol-7.5% acetic acid) were placed in Saran wrap, and exposed for  16-40  h  to 
Kodak XAR-5  film at -80°C  between DuPont Cronex Par-Speed intensifying screens 
(DuPont Co., Wilmington, DE). 
Results 
PA Secreted by Monocytes-Macrophages  and U 937 Cells Is of the Uh Type.  Human 
monocytes-macrophages and U  937 cells cultured in serum-free medium secrete 
PA.  To  determine  the  type  of  enzyme  released  by  these  cells,  samples  of 
conditioned media were mixed with specific anti-Uk and anti-TA IgG, and the 
immune complexes precipitated by the addition of fixed S.  aureus.  Aliquots of 
the supernatants and immune precipitates were subjected to SDS-PAGE, and the 
gels analyzed by zymography (Fig.  1).  Monocyte-macrophage-conditioned me- 
dium contained one major form of PA activity (track bl);  the migration of this 
PA in the electrophoretic gel was identical to that of a  standard of Mr 55,000 
human  Uk  (track  al),  and  different from  that  of HeLa  cells  TA  (track  dl). 
Monocyte-macrophage PA was quantitatively recovered in the immune precipi- 
tate in the presence of anti-Uk IgG (tracks b2), but remained in the supernatants 
of the immunoprecipitation reactions in presence of irrelevant IgG (tracks bl) or 
of anti-TA  IgG  (tracks  b3).  Identical  results  were  obtained  with  conditioned 
medium  from  U  937  cells  (tracks  c).  In  addition,  the  increased  levels  of PA 
present in conditioned media from PMA (100  ng/ml)- or concanavalin A  (10 
ug/ml)-treated  monocytes-macrophages and  U  937  cells could be entirely ac- 
counted for by an increase in the production of the same enzyme. Thus, all the 
PA  produced  by  monocytes-macrophages and  U  937  cells  is  immunologically 
related to Uk, but not to TA. 
The nature of the Mr 100,000 lytic zones that developed in the zymograms of 
monocyte-macrophage and  U  937-conditioned  media is not entirely clear; al- 
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FIGURE  1.  Immunoprecipitation  of PA secreted by monocytes-macrophages and U 937 cells. 
Samples (20 •1)  of Mr 55,000  human Uk (0.2 U/ml) (tracks a), of conditioned medium from 
human monocytes-macrophages  (tracks b), from U 937 cells (tracks c), or from PMA-treated 
HeLa cells (a source of human TA  ~) (tracks d), were mixed with IgG from uninjected rabbits 
(2 ttg, tracks  I), or from rabbits immunized against human Uk (0.4 t~g, tracks 2) or against 
human TA (2 #g, tracks 3). After SDS-PAGE of the supernatants and eluted pellets from the 
immunoprecipitations,  the gels were analyzed by zymography. Zones of lysis did not develop 
when plasminogen was omitted from the zymogram. Molecular weights were calculated from 
the position of markers (Pharmacia, low molecular weight calibration kit) electrophoresed  in 
parallel lanes and stained with Coomassie Brilliant Blue R 250. 
that they were absent from the anti-Uk supernatants, but remained in the anti- 
TA  supernatants, suggested that they were due to  Uk-related forms of PA.  In 
view of the results reported in later sections of this paper, we believe that these 
lytic zones are due to the activity of covalent complexes between Uk and a  PA 
2 Human TA has a Mr of 72,000. A TA-related form of PA with a MT of 110,000 was also present 
in conditioned medium from  HeLa cells (A, tracks  dl  and 2); it probably consists of a complex 
between the enzyme and a cell-derived ligand, as discussed further in the case of Uk and U 937 cells 
or monocytes. TA-containing  immune  complexes did not dissociate completely before electrophoresis 
(the samples being neither boiled nor reduced), resulting in the presence of high Mr species of PA in 
this sample (B, track d3). VASSALLI ET  AL.  1657 
inhibitor; different levels ofplasmin contamination in the IgG preparations could 
explain the variable amounts of such complexes. 
U  937  Cells Secrete an  Inhibitor  of Fibrinolysis.  To  assay for  the  presence  of 
inhibitor(s)  of Uk-catalyzed  fibrinolysis in  the  conditioned  medium of U  937 
cells, a  constant amount of Mr 55,000  Uk was added to increasing amounts of 
medium. After 30 min of incubation at 4°C, the samples were assayed in [125I]- 
fibrin-coated wells, in the presence of plasminogen. Fibrinolysis was completely 
prevented when Uk had been preincubated with as little as 1.5 #1 of conditioned 
medium (Fig. 2). This suggested that U  937 cells released an inhibitor(s) of Uk 
and/or plasmin. Further experiments were designed to investigate the possible 
interaction of Uk with this inhibitor. 
The Inhibitor  Released by U 937 Cells Forms a Covalent Complex with Uk, and This 
Complex Is Enzymatically  Inactive.  Covalent complexes between  proteolytic en- 
zymes  and  their  inhibitors  have  been  observed  in  many  systems  (29).  The 
formation of such complexes can be used to assay for the presence of protease 
inhibitors. Mr 55,000  [12~I]-Uk  was added to U  937-conditioned medium; after 
60 min at 4°C, SDS-containing electrophoresis sample buffer was added and the 
boiled sample subjected to SDS-PAGE.  Autoradiography of the fixed gel (Fig. 
3)  revealed  that almost all  the  radioactivity migrated with an apparent Mr  of 
94,000  (track  2).  This  indicated  that  [~sI]-Uk  had  formed  an  SDS-resistant 
complex with a component present in U 937 medium. Addition of unlabeled Uk 
prevented  formation  of the  radioactive  M~  94,000  complex  (track  3);  thus, 
complex formation with [125I]-enzyme could be competed by unlabeled enzyme, 
suggesting that  interaction of Uk  with the  U  937-secreted  ligand was not an 
exclusive property of the iodinated molecule. 
To  determine  whether  binding  of  Uk  to  this  ligand  was  associated  with 
inhibition of enzymatic activity, we used Mr 33,000  Uk, a proteolytic product of 
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FIGURE 2-  Inhibition of Uk-catalyzed  fibrinolysis  by conditioned medium from U 937 cells. 
Uk (3 mU) was added to dilutions of U 937-conditioned medium (0.1 to 5 td in a total volume 
of 20 #1 RPMI  1640 plus  1 mg/ml BSA). After 30 min at 4°C,  the samples were assayed in 
[125I]-fibrin-coated  wells in presence of plasminogen. Enzymatic activity remaining in the 
samples was determined by comparison with a standard curve of Uk (0.3-3  mU). U 937 
medium without added  Uk did not catalyze any fibrinolysis  under the conditions of this 
experiment; in the absence of U 937 medium, 3 mU Uk catalyzed the lysis of 15% of the 
available substrate. 1658  UROKINASE  AND  INHIBITOR  IN  HUMAN  MONOCYTES-MACROPHAGES 
FIGURE 3.  Formation  of a  complex between  [1251]-Uk and a  U  937-produced  ligand. Mr 
55,000  [125I]-Uk (0.5  ng) was added to 20-#1 samples of fresh medium (track  1), of U  937- 
conditioned medium (track 2), or of U  937-conditioned medium containing 10 ng unlabeled 
Uk (track 3).  After 1 h at 4°C an equal volume of double-strength sample buffer was added 
and  the  samples  were boiled and  subjected  to  SDS-PAGE. The  fixed and  stained  gel was 
analyzed by autoradiography.  Molecular weights were calculated from the position of markers 
in the stained gel. 
between the endogenous M~ 55,000 enzyme and the exogenously added Uk. Mr 
33,000  [125I]-Uk was mixed with U  937  medium, and aliquots of the sample 
were subjected to SDS-PAGE. Part of the gel was processed for autoradiography 
(Fig.  4A), and part for zymography (Fig.  4B).  Whereas 60%  of the [125I]-label 
was recovered at Mr 72,000, in the form of the enzyme-ligand complex, no Mr 
72,000 PA activity could be detected by the zymogram. Since the free Mr 33,000 
[125I]-Uk remaining after incubation with U  937  medium was mostly inactive, 
almost  all  the  active  enzyme present  in  our  [125I]-Uk preparation  had  been 
inactivated upon binding to the ligand. With longer incubation of the zymogram, 
enzymatic activity of the Mr 72,000 complex did become detectable (data not 
shown); this low activity may reflect the lability of the inhibitor in SDS (unpub- 
lished observations). 
Thus, culture medium from U 937 cells contained a ligand for human Uk; the 
enzyme-ligand covalent complex had an apparent Mr of 94,000 with Mr 55,000 VASSALLI  ET  AL.  1659 
FIGURE 4.  The  complex  between  Uk  and  the  U  937-produced  ligand  is  enzymatically 
inactive. Mr 33,000 ['2sI]-Uk was added to fresh medium (tracks 1) or to U 937-conditioned 
medium (tracks 2). After 1 h at 4°C, double-strength  sample buffer was added and duplicate 
aliquots of the samples were electrophoresed  in a  10% polyacrylamide SDS-containing  slab 
gel; U 937 medium without [~2~I]-Uk  added was also electrophoresed  in the same gel (track 
3). The gel was cut in two parts. Part A was processed for autoradiography;  for quantitation, 
the gel was cut and slices counted in a gamma counter. Part B was processed for zymography. 
Uk, and  72,000  with Mr  33,000  Uk,  indicating  that the ligand,  when bound  to 
Uk,  had  a  Mr of 39,000.  Since  the  complexed enzyme was functionally  inacti- 
vated,  this  ligand  can  thereby  be  considered  as  an  inhibitor  of Uk.  We  can 
calculate  (from the  data  of Fig.  3)  that  the concentration  of this inhibitor  in  U 
937  medium  was  sufficient  to  totally  account  for the  inhibition  of fibrinolysis 
illustrated in  Fig.  2. 
The  Uk Secreted by  U 937  Cells Is  a  Proenzyme.  The  results  reported  in  the 
preceding  sections  demonstrated  the  apparently  paradoxical  coexistence,  in  U 
937  culture  medium,  of  a  Mr  55,000  form  of  Uk  that  could  be  detected 
catalytically  by  zymography (Fig.  1)  and  of a  component  that  reacted  rapidly 
with  exogenously added  [125I]-Uk to form a  stable,  inactive complex of higher 
Mr  (Figs.  3  and  4).  Such  a  result  would  in  fact  be expected  if the  Uk  activity 1660  UROKINASE  AND  INHIBITOR IN  HUMAN  MONOCYTES-MACROPHAGES 
detected  in  the  culture  medium  was  due  to  a  form  of the  enzyme  that  was 
inactive before zymography, and therefore that could not have reacted with the 
available ligand.  Uk  has  been  shown  to  be secreted  by certain  cell  types as an 
inactive zymogen (proUk), which can become activated under the effect of trace 
amounts of plasmin present in the plasminogen used for zymographic detection 
of Uk activity (10-12,  14).  ProUk consists of a  single polypeptide chain;  it does 
not  activate  plasminogen,  nor  does  it  react  with  DFP,  an  inhibitor  of serine 
esterases. Plasmin cleaves proUk to generate the two-chain active enzyme, which 
can be irreversibly inhibited by reaction with DFP (10-12,  14). 
We have used the  DFP  inhibition  and plasmin activation reactions to charac- 
terize the form of Uk present in  U  937  medium (Fig.  5).  Active Mr 55,000  Uk 
(track cl)  was totally inactive after reaction  with  DFP  (track c3); by contrast,  U 
937-secreted  Uk  (track al)  was  unaffected  by  DFP  (track a3).  The  activity of 
Uk  was  not  altered  by  exposure  to  plasmin  (track  c2),  whereas  the  U  937- 
secreted  enzyme  was  undetectable  after  such  treatment  (track  a2);  this  result 
would  be expected  if plasmin  converted the  U  937-secreted  molecule  into  an 
active form,  which  could  react with and be inactivated by the available ligand. 
To further substantiate  this hypothesis, we took advantage of the lability of the 
inhibitor  in  presence of propanol  (unpublished  observations).  Propanol did  not 
alter the activity of Uk, nor its susceptibility to DFP (tracks d  1-4).  In propanol- 
treated U  937  medium Uk activity remained resistant to DFP inactivation (track 
b3);  plasmin  did  not  cause  the  disappearance  of  Uk  activity  (track  b2),  but 
FIGURE 5.  Zymographic analysis of U 937-produced Uk: effects of propanol, plasmin, and 
DFP. U 937-conditioned  medium and Mr 55,000 Uk (0.6 U/ml in fresh medium) were treated 
in parallel. Samples were exposed first to propanol,  second to plasmin, and third  to DFP, as 
indicated. Propanol was added to a final concentration of 40% (tracks b and d); both propanol- 
treated and untreated samples were lyophilized in a Savant SpeedVac apparatus and reconsti- 
tuted  to the original volume with H~O. Plasmin treatment (1  /tg/ml) was for 1 h at 37°C 
(tracks 2 and 4). DFP treatment (10 raM) was for 1 h at 20°C (tracks 3 and 4). Samples were 
mixed with an equal volume of double-strength  sample buffer, and subjected to SDS-PAGE. 
The gel was processed for zymograpby. VASSALLI  ET  AL.  1661 
rendered it totally susceptible to inactivation by DFP (track b4).  Furthermore, 
exposure of propanol-treated medium to  plasmin accelerated  the  kinetics  of 
substrate lysis catalyzed by the U 937-secreted form of Uk (Fig. 6). 
Taken  together,  these  results  suggest that  U  937  cells  secrete  Uk  as  the 
inactive, DFP-resistant, proenzyme. Plasmin converts this proUk into active Uk, 
which is rapidly complexed to and inhibited by the U  937-secreted ligand. In 
the absence of functional inhibitor, i.e., after exposure to propanol, active Uk 
accumulates in U 937 medium supplemented  with plasmin, and can be inactivated 
by reaction with DFP. 
Human  Monocytes-macrophages  in  Culture  Secrete ProUk  and  a  Ligand for  Uh. 
Freshly isolated human monocytes-macrophages secreted a Mr 55,000 form of 
Uk (Fig.  1),  which was also resistant to inactivation by DFP (data not shown). 
Hence, like U 937 cells, monocytes-macrophages secrete proUk. 
Addition of  Mr 33,000 [125I]-Uk to monocyte-macrophage  conditioned medium 
resulted in the formation of a Mr 72,000 radioactive complex (Fig.  7, track 5), 
that co-migrated with the complex formed with the U 937-produced Uk inhib- 
itor (track 2).  As shown in  Fig.  4  for the  U  937  complex, Uk present in  the 
monocyte complex was  also  functionally inactivated (data  not  shown).  Thus, 
freshly prepared human monocytes-macrophages  release a Uk ligand comparable 
to that of U 937 cells. 
FIGURE 6.  Plasmin-catalyzed activation of U  937-secreted proUk.  U  937-conditioned me- 
dium was treated with propanol as in Fig. 5, and incubated for 1 h at 37°C without (tracks 1) 
or with addition of plasmin (1  #g/ml) (tracks 2).  The samples were electrophoresed and the 
gel processed for zymography. Photographs were taken after 8 and  16 h of incubation of the 
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FIGURE 7.  Formation of complexes between [l~I]-Uk and U 937- or monocyte-macrophage- 
produced ligand; lack of competition by thrombin. Mr  33,000 [12*I]-Uk (2  ng,  l06 cpm/#g) 
was added to 10-#1 samples of fresh medi.um (track 1), U 937-conditioned medium (tracks 2- 
4), or monocyte-conditioned medium (tracks 5-7), in the absence of (tracks 1, 2, 5) or 15 rain 
after addition of unlabeled thrombin (0.2 #g) (tracks 3, 6) or unlabeled  Mr 33,000 Uk (0.2 #g) 
(tracks 4,  7). After  1 h  at 4°C, the samples were subjected to SDS-PAGE, and analyzed by 
autoradiography. 
The Uk Inhibitor Secreted by Monocytes-Macrophages and U 937 Cells Is not a Ligand 
for Thrombin.  Cultured human fibroblasts secrete protease-nexin, an inhibitor 
of Uk that forms SDS-resistant complexes with either Uk or thrombin (13). The 
reported Mr of Uk complexed with protease-nexin is comparable to that obtained 
with  the  monocyte-released ligand.  It  was  therefore of interest  to  determine 
whether the  ligands  secreted by  these  different cell  types  shared  additional 
properties. 
In contrast to Uk (Fig. 7, tracks 4 and 7), thrombin did not prevent the binding 
of [125I]-Uk to the ligand from U 937 cells or monocytes-macrophages (tracks 3 
and 6). Furthermore, no complex formation was observed when [~25I]-thrombin 
was added to U 937 medium (Fig. 8, track 3) or monocyte-macrophage medium 
(data not shown), whereas fibroblast culture medium did contain ligand(s) for 
both  thrombin  and  Uk  (Fig.  8,  tracks  2  and  5).  Heparin  (2  U/ml),  which 
accelerates the reaction of thrombin with protease-nexin (13), had no effect on 
the outcome of these experiments (data not shown). Thus, the monocyte-secreted 
inhibitor of Uk did not react with thrombin. Finally, the complex formed between 
[125I]-Uk and the U  937  ligand was clearly resolved from that formed with the 
fibroblast ligand (Fig. 8, tracks 5 and 6). In conclusion, the monocyte ligand and 
fibroblast-produced protease-nexin are different inhibitors. VASSALLI  ET  AL.  1663 
FIGURE 8.  Formation of complexes between [125I]-thrombin  or [l~sI]-Uk and fibroblast- or 
U 937-produced ligands. ['~sI]-thrombin (2 ng, 106 cpm/#g) (tracks 1-3) or Mr 33,000 [12sI]- 
Uk (2 ng, l0  s cpm/#g) (tracks 4-6) were added to  10 #l samples of fresh medium (tracks 1 
and 4), fibroblast-conditioned  medium (tracks 2 and 5), or U 937-conditioned medium (tracks 
3  and  6).  After  1  h  at  4°C  the  samples  were  subjected to  SDS-PAGE, and analyzed by 
autoradiography. 
Discussion 
The studies reported in this paper establish some of the characteristics of PA 
secretion by cultured human monocytes and by cells from the histiocytic lym- 
phoma line U 937. 
--First, the enzyme produced by these cells has an apparent Mr of 55,000 by 
SDS-PAGE, and co-migrates with Uk purified from human urine. Moreover, it 
is recognized by antibodies raised against human Uk, but not by antibodies to 
human TA; we can therefore exclude the contribution of a form of PA recently 
described in  certain acute myeloblastic leukemia cells that  is  immurtologically 
related to TA and not to Uk, but that co-migrates electrophoretically with Uk 
(30). Thus, monocytes-macrophages purified from human peripheral blood, like 
granulocytes (30, 31), secrete Uk as their only type of PA. 
--Second, the form of Uk that accumulates in the serum-free culture medium 
is not inhibitable  by DFP,  but it can be converted to a  DFP-sensitive form by 
plasmin. By these criteria, it behaves like the proUk secreted by human carcinoma 
and glioblastoma cell lines (10,  11),  and by cultured fibroblasts (14).  Whether 1664  UROKINASE  AND INHIBITOR IN  HUMAN MONOCYTES-MACROPHAGES 
monocytes-macrophages also secrete active Uk, in addition to proUk, cannot be 
decided at this time: indeed, active enzyme would be rapidly inhibited by the co- 
secreted ligand, and such enzyme-inhibitor complexes may be catabolized by the 
cells (32), or, if remaining in the medium, would have only low specific enzymatic 
activity  in  our  assays.  Biosynthetic  labeling  of cellular  proteins  followed by 
immunoprecipitation of Uk-related polypeptides will be necessary to resolve this 
issue. 
--Third, an inhibitor of fibrinolysis is released by the cells in culture. Exoge- 
nously added active Uk forms with this inhibitor a complex that is not dissociated 
by boiling in SDS, and that is functionally inactivated as a PA. The apparent Mr 
of the complex is ~39,000 daltons higher than that of free Uk; gel filtration of 
the ligand-inhibitor indicates a Mr of 40,000 before reaction with Uk (in prepa- 
ration).  Taken together,  these data suggest the formation of a  1:1  Uk-ligand 
complex. The ligand does not react with thrombin, nor with plasmin (unpub- 
lished observations); thus it is different from protease-nexin, a protease inhibitor 
released by human fibroblasts that forms similar complexes with Uk and throm- 
bin  (13).  A  further characterization of the monocyte-macrophage inhibitor  is 
under way: since the inhibitor can be detected amongst biosynthetically labeled 
products of U  937 cells, it must be synthesized during the culture; the currently 
available data allow it to be distinguished from all characterized inhibitors, with 
the possible exception of the fibrinolytic inhibitor originally described in human 
placenta (33, 34). 
--Fourth, proUk and the Uk inhibitor are released concomitantly by mono- 
cyte-macrophage cultures,  although  we  have  not  determined  whether  both 
proteins are secreted by the same cells at the same time. From the data presented 
here, we can estimate that the free inhibitor is in large (10-100-fold) excess over 
proUk. Since proUk is catalytically inactive and does not react with the inhibitor, 
both proteins can coexist separately in the same media. In the presence of trace 
amounts of plasmin, or perhaps of some other proteases capable of converting 
proUk  to  the  active  enzyme,  Uk  is  generated and  reacts with  the  available 
inhibitor. Thus, the presence of Uk and its inhibitor may appear to be mutually 
exclusive, as has been reported for mouse macrophages (15,  16), when plasmin- 
ogen was added to the unfractionated sample; alternatively, both can be detected 
as shown in our study, in which the proenzyme was separated from the inhibitor 
before exposure to plasminogen. 
--Fifth, U 937 cells do not differ from cultured monocytes-macrophages with 
respect to proUk and inhibitor production. The use of this cell line overcomes 
possible problems that could arise from the contamination of freshly prepared 
monocyte preparations by other cell types. The U  937 line therefore provides a 
convenient source for the further study of these processes. 
The concomitant secretion of proUk and of an inhibitor of Uk has recently 
been  reported for cultured human fibroblasts  (14).  Our  results extend these 
observations  to  another  cell  type.  We  have  also  shown  that  the  monocyte- 
produced inhibitor  is  different from the fibroblast protease-nexin.  Thus,  the 
regulation of extracellular PA activity in both fibroblasts and monocytes-macro- 
phages, and possibly in other cell types, may involve, in addition to transcriptional 
events (35), controls at the posttranslational level as well as through the produc- VASSALLI ET AL.  1665 
tion of enzyme inhibitors. Furthermore, these inhibitors appear to differ between 
different cell  types.  The  secretion of Uk  inhibitors  by murine macrophages, 
which also synthesize a  Uk-type PA (15,  16,  manuscript in preparation), as well 
as by hepatoma tissue culture cells (36), endothelial cells (37-39), and other cell 
types (40-42), further underlines the possible generality of these phenomena. 
The  physiological  role  of  monocyte-macrophage PA  remains  conjectural. 
Studies on the modulation of enzyme production suggest that it may be involved 
in the proteolytic events that accompany cell migration (1, 2), and macrophage- 
mediated digestion of certain extracellular matrices has been shown to require 
PA activity (43).  Whether proUk activation and/or Uk inhibitor secretion are 
modulated as a function of mononuclear phagocyte differentiation can be deter- 
mined by  further studies.  The  DFP-inactivation  assay  that  we  have  used  to 
distinguish  between  proUk  and  Uk  allows  easy  evaluation  of the  zymogen/ 
enzyme ratio in conditioned media. Also, formation of SDS-resistant [l~sI]-Uk- 
inhibitor complexes can be used to quantitate the available inhibitor; using this 
approach  we  have  observed  that  production  of a  comparable  Uk  ligand  by 
murine peritoneal macrophages varies with the inflammatory status of the animal 
(A. Wohiwend et al., in preparation). We have recently described the presence 
of high affinity binding sites specific for Mr 55,000  Uk on the surface of U  937 
cells and human peripheral blood mononuclear cells.  3 DFP-inactivated Mr 55,000 
Uk also binds to these cells, whereas Mr 33,000 Uk does not; we have therefore 
proposed that determinants of the A chain of Mr 55,000 Uk are involved in this 
binding, and that the enzyme need not be active for binding to occur. In view 
of the findings described in this paper, it will be of interest to determine whether 
proUk also can bind to U  937 and other cells, and whether cell-bound enzyme 
is susceptible to inhibition by the secreted ligand. The results of such experiments 
should  allow  us  to  better  evaluate a  potential  role  for  Uk  in  the  biology of 
mononuclear phagocytes. 
Summary 
The plasminogen activator (PA) produced by freshly purified human mono- 
cytes-macrophages and histiocytic, lymphoma-derived U  937 cells was analyzed 
by zymography after sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE), and found to migrate with an apparent Mr of 55,000,  identical to 
that of urokinase (Uk). By immunoprecipitation with antibodies specific for the 
two different types of PA, the enzyme was shown to be immunologically related 
to urokinase,  and not to tissue PA.  Urokinase  was secreted in the form of the 
inactive Mr 55,000 zymogen prourokinase, and could be converted to the active 
Mr 55,000 enzyme by limited proteolysis with plasmin. 
Conditioned media from cultures of U 937 cells and monocytes-macrophages 
inhibited the fibrinolytic activity of exogenously added urokinase. Using [~25I]- 
labeled  urokinase  we  observed  the  formation  of an  enzyme-ligand complex, 
which was not dissociated by boiling in SDS and migrated with an apparent Mr 
40,000  daltons  higher than  the free enzyme; since complexed urokinase was 
functionally inactivated as a  PA,  the ligand is an  inhibitor of urokinase.  This 
3J.-D. Vassalli, D. Baccino,  and D, Belin, A cellular binding site for the Mr 55,000 form of human 
urokinase; manuscript  submitted  for publication. 1666  UROKINASE AND  INHIBITOR IN  HUMAN MONOCYTES-MACROPHAGES 
inhibitor is different from fibroblast-produced protease-nexin, in that it did not 
interact wi~h thrombin. 
These results suggest that plasminogen activation by mononuclear phagocytes 
can  be  modulated  through  the  secretion  of both  (pro)enzyme  and  a  specific 
inhibitor. 
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